Stock CTSO CYTOSORBENTS CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Cytosorbents Corp OTC Bulletin Board

Equities

CTSO

US23283X1072

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
GL
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
GL
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M
MT
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
GL
Transcript : Cytosorbents Corporation, Q4 2023 Earnings Call, Mar 14, 2024
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
GL
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
GL
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
GL
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
AQ
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
North American Morning Briefing : Stock Futures Struggle After Weak China Data
DJ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50
MT
S&P 500 ekes out meager gains, flirts with bull market confirmation
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTSO Stock
  4. CTSO Stock
  5. News Cytosorbents Corp